Cargando…

Early prediction of blonanserin response in Japanese patients with schizophrenia

BACKGROUND: Blonanserin is a second-generation antipsychotic used for the treatment of schizophrenia in Japan and Korea. The present study aimed to examine early prediction of blonanserin in patients with schizophrenia. METHODS: An 8-week, prospective, single-arm, flexible-dose clinical trial of blo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kishi, Taro, Matsuda, Yuki, Fujita, Kiyoshi, Iwata, Nakao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181750/ https://www.ncbi.nlm.nih.gov/pubmed/25285009 http://dx.doi.org/10.2147/NDT.S70227

Ejemplares similares

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
por: Kishi, Taro, et al.
Publicado: (2016)

Cardiometabolic Risks of Blonanserin and Perospirone in the Management of Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Kishi, Taro, et al.
Publicado: (2014)

Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials
por: Kishi, Taro, et al.
Publicado: (2015)

Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population
por: Kishi, Taro, et al.
Publicado: (2017)

Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study
por: Iwata, Nakao, et al.
Publicado: (2019)

Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine
por: Kishi, Taro, et al.
Publicado: (2014)

Profile of blonanserin for the treatment of schizophrenia
por: Tenjin, Tomomi, et al.
Publicado: (2013)

Quetiapine extended‐release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis
por: Kishi, Taro, et al.
Publicado: (2019)

Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone
por: Hori, Hikaru, et al.
Publicado: (2014)

PM397. Effectiveness of blonanserin in patients with schizophrenia: A systematic review and meta-analysis of direct head-to-head comparisons with other antipsychotics
por: Kishi, T., et al.
Publicado: (2016)

Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials
por: Kishi, Taro, et al.
Publicado: (2018)

Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2016)

Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies
por: Murasaki, Mitsukuni, et al.
Publicado: (2021)

S220. BLONANSERIN AUGMENTATION IN PATIENTS WITH SCHIZOPHRENIA – WHO IS BENEFITED FROM BLONANSERIN AUGMENTATION? AN OPEN-LABEL, PROSPECTIVE, MULTI-CENTER STUDY
por: Bahk, Won-Myong, et al.
Publicado: (2018)

PM423. Blonanserin augmentation in patients with schizophrenia – who is benefited from blonanserin augmentation?: An open-label, prospective, multicenter study
por: Woo, Young Sup, et al.
Publicado: (2016)

Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis
por: Kishi, Taro, et al.
Publicado: (2018)

Memantine treatment for Japanese patients with moderate to severe Alzheimer’s disease: a meta-analysis of double-blind, randomized, placebo-controlled trials
por: Kishi, Taro, et al.
Publicado: (2018)

Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2019)

Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8‐week, double‐blind, multicenter, randomized controlled study
por: Harvey, Philip D., et al.
Publicado: (2019)

Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
por: Zhao, Yueren, et al.
Publicado: (2013)

Classifying Schizophrenia Cases by Artificial Neural Network Using Japanese Web-Based Survey Data: Case-Control Study
por: He, Yupeng, et al.
Publicado: (2023)

Blonanserin-induced Mood Alteration in Schizophrenia and Schizoaffective Disorder: Two Cases
por: Min, Aran, et al.
Publicado: (2013)

Assessment of the Latent Adverse Events of Antipsychotic Treatment Using a Subjective Questionnaire in Japanese Patients with Schizophrenia
por: Hatano, Masakazu, et al.
Publicado: (2017)

Prediction of Corresponding Dose of Transdermal Blonanserin to Oral Dose Based on Dopamine D(2) Receptor Occupancy: Unique Characteristics of Blonanserin Transdermal Patch
por: Tomita, Yoshiko, et al.
Publicado: (2022)

A case of schizophrenia with relapsed catatonia successfully treated with blonanserin transdermal patch
por: Hagikura, Minako, et al.
Publicado: (2023)

Striatal Dopamine D(2) Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia
por: Nishibe, Hironori, et al.
Publicado: (2020)

Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Oya, Kazuto, et al.
Publicado: (2015)

Evaluation of dopamine D(3) receptor occupancy by blonanserin using [(11)C]-(+)-PHNO in schizophrenia patients
por: Sakayori, Takeshi, et al.
Publicado: (2020)

Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Okuyama, Yuji, et al.
Publicado: (2016)

Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

PM498. Investigation of feelings toward taking blonanserin and risperidone in schizophrenia patients: part 2
por: Shoji, Yoshihisa, et al.
Publicado: (2016)

Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report
por: Sakai, Shintaro, et al.
Publicado: (2021)

Effect of Adenine on Clozapine-induced Neutropenia in Patients with Schizophrenia: A Preliminary Study
por: Takeuchi, Ippei, et al.
Publicado: (2015)

Simple and Sensitive Analysis of Blonanserin and Blonanserin C in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry and Its Application
por: Zheng, Yunliang, et al.
Publicado: (2014)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi, Taro, et al.
Publicado: (2017)

Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8‐week, multicenter, double‐blind, randomized controlled study
por: Harvey, Philip D., et al.
Publicado: (2019)

Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder
por: Nagao, Kei, et al.
Publicado: (2013)

A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression
por: Kishi, Taro, et al.
Publicado: (2023)

Body composition in Japanese patients with psychiatric disorders: A cross‐sectional study
por: Kishi, Taro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c1shk6pknsla0cjodb6m6j01ei